MedTrace Logo

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

NCT01750905 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-08-30

No results posted yet for this study

Summary

The most promising chimeric natriuretic peptide designed and studied by our group has been CD-NP which has anti-fibrotic and cardioprotective properties in vivo, vitro and in normal volunteers and human heart failure patients. Since left ventricular assist device (LVAD) can not reverse remodeling of the heart whereas it can improve hemodynamics, CD-NP may be novel anti-fibrotic and anti-remodeling drug as co-therapy during LVAD support.

Conditions

  • Left Ventricular Insufficiency

Interventions

DRUG

CD-NP

CD-NP 5 ug/kg subcutaneous injection (SQ)

DRUG

Placebo

Vehicle (D5W) SQ

Sponsors & Collaborators

Principal Investigators

  • John Schirger, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-05-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01750905 on ClinicalTrials.gov